Needham Downgrades Heron Therapeutics to Hold

Benzinga Newsdesk www.benzinga.com Negative 86.3%

Neg 86.3% Neu 0% Pos 0%

Needham analyst Serge Belanger downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Hold.

Comments

No comments yet. Be the first!